These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 36258702)

  • 1. Steven-Johnson Syndrome: A Rare but Serious Adverse Event of Nivolumab Use in a Patient With Metastatic Gastric Adenocarcinoma.
    Saad E; Adhikari P; Antala D; Abdulrahman A; Begiashvili V; Mohamed K; Ali E; Zhang Q
    J Med Cases; 2022 Sep; 13(9):449-455. PubMed ID: 36258702
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Steven-Johnson Syndrome/Toxic Epidermal Necrolysis is Associated with PD-1/PD-L1 Inhibitors Usage: A Case Series.
    Cao R; Xu T
    Br J Hosp Med (Lond); 2024 Sep; 85(9):1-11. PubMed ID: 39347662
    [No Abstract]   [Full Text] [Related]  

  • 3. Case Series of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis With Nivolumab and Nivolumab/ Ipilimumab Combination Therapy in Metastatic Melanoma.
    Lee O; Masood M; Nutan F
    J Drugs Dermatol; 2022 May; 21(5):529-530. PubMed ID: 35533039
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Stevens-Johnson syndrome and toxic epidermal necrolysis-like reactions to checkpoint inhibitors: a systematic review.
    Maloney NJ; Ravi V; Cheng K; Bach DQ; Worswick S
    Int J Dermatol; 2020 Jun; 59(6):e183-e188. PubMed ID: 32052409
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of toxic epidermal necrolysis by a multidisciplinary team. A review of literature and treatment results.
    Papp A; Sikora S; Evans M; Song D; Kirchhof M; Miliszewski M; Dutz J
    Burns; 2018 Jun; 44(4):807-815. PubMed ID: 29627131
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Stevens-Johnson syndrome and toxic epidermal necrolysis: a 10-year experience in a burns unit.
    Houschyar KS; Tapking C; Borrelli MR; Nietzschmann I; Puladi B; Ooms M; Rein S; Houschyar M; Duscher D; Maan ZN; Reumuth G; Branski LK; Modabber A; Kluwig D; Schmitt L; Philipp-Dormston WG; Yazdi AS; Siemers F
    J Wound Care; 2021 Jun; 30(6):492-496. PubMed ID: 34121430
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Late-onset Stevens-Johnson syndrome due to nivolumab use for hepatocellular carcinoma.
    Dasanu CA
    J Oncol Pharm Pract; 2019 Dec; 25(8):2052-2055. PubMed ID: 30782092
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pembrolizumab-induced Toxic Epidermal Necrolysis in a Patient with Metastatic Esophageal Adenocarcinoma.
    Gallo Marin B; Oliva R; Kahn B; Borgovan T; Brooks BE; Massoud CM
    R I Med J (2013); 2022 Apr; 105(3):34-36. PubMed ID: 35349618
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Striking enhancement at the site of radiation for nivolumab-induced Stevens-Johnson syndrome.
    Shah KM; Rancour EA; Al-Omari A; Rahnama-Moghadam S
    Dermatol Online J; 2018 Jun; 24(6):. PubMed ID: 30142712
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antecedent Drug Exposure Aetiology and Management Protocols in Steven-Johnson Syndrome and Toxic Epidermal Necrolysis, A Hospital Based Prospective Study.
    Farhat S; Banday M; Hassan I
    J Clin Diagn Res; 2016 Jan; 10(1):FC01-4. PubMed ID: 26894082
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Current Perspectives on Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis.
    Lerch M; Mainetti C; Terziroli Beretta-Piccoli B; Harr T
    Clin Rev Allergy Immunol; 2018 Feb; 54(1):147-176. PubMed ID: 29188475
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epidermal programmed cell death-ligand 1 expression in TEN associated with nivolumab therapy.
    Vivar KL; Deschaine M; Messina J; Divine JM; Rabionet A; Patel N; Harrington MA; Seminario-Vidal L
    J Cutan Pathol; 2017 Apr; 44(4):381-384. PubMed ID: 28000240
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pembrolizumab-Associated Stevens-Johnson Syndrome in a Patient With Metastatic Non-small Cell Lung Cancer: A Case Report.
    Sandhu M; Kc B; Bhandari J; Gambhir HS; Farah R
    Cureus; 2023 Jul; 15(7):e41439. PubMed ID: 37546048
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adverse cutaneous toxicities by PD-1/PD-L1 immune checkpoint inhibitors: pathogenesis, treatment, and surveillance.
    Bhardwaj M; Chiu MN; Pilkhwal Sah S
    Cutan Ocul Toxicol; 2022 Mar; 41(1):73-90. PubMed ID: 35107396
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phenytoin induced Steven-Johnson syndrome and bronchiolitis obliterans - case report and review of literature.
    Pannu BS; Egan AM; Iyer VN
    Respir Med Case Rep; 2016; 17():54-6. PubMed ID: 27222786
    [TBL] [Abstract][Full Text] [Related]  

  • 16. From the Cochrane Library: Systemic Interventions for Steven-Johnson Syndrome (SJS), Toxic Epidermal Necrolysis (TEN), and SJS/TEN Overlap Syndrome.
    Pathak GN; Truong TM; Singal A; Taranto V; Rao BK; Jacobsen AA
    JMIR Dermatol; 2024 Jan; 7():e46580. PubMed ID: 38289652
    [No Abstract]   [Full Text] [Related]  

  • 17. Combination Therapy of Ipilimumab and Nivolumab-associated Toxic Epidermal Necrolysis (TEN) in a Patient With Metastatic Melanoma: A Case Report and Literature Review.
    Logan IT; Zaman S; Hussein L; Perrett CM
    J Immunother; 2020 Apr; 43(3):89-92. PubMed ID: 31651559
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Steven-Johnson Syndrome Induced by Lamotrigine and Valproic Acid in a Pediatric Patient: A Case Report.
    Espinosa-Aguilar EJ; Piña-Ballantyne SA; Espinosa-Aguilar KL; Tun-Pisté JC; Calderón-Garcidueñas AL
    Cureus; 2023 Jul; 15(7):e41267. PubMed ID: 37533620
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SJS/TEN immune-related dermatologic reaction secondary to immune checkpoint inhibitor pembrolizumab in skin of color.
    Pierre AB; Jernigan AM; Castellano T
    Gynecol Oncol Rep; 2023 Dec; 50():101290. PubMed ID: 37868017
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Toxic epidermal necrolysis and Stevens-Johnson syndrome/toxic epidermal necrolysis overlap in pediatric patients with a focus on newer antiepileptic drugs: A 25-year retrospective study at a single tertiary care center.
    Gleghorn KL; Voigt C; Kelly B
    Pediatr Dermatol; 2021 Jul; 38(4):812-818. PubMed ID: 34060145
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.